HC Wainwright & Co. Initiates Coverage On Lyra Therapeutics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on Lyra Therapeutics (NASDAQ:LYRA) with a Buy rating and a price target of $12.
August 31, 2023 | 10:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lyra Therapeutics has been initiated with a Buy rating by HC Wainwright & Co. with a price target of $12.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target of $12 indicates a positive outlook for Lyra Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100